Navigation Links
Lilly CEO Calls for Biopharmaceutical Industry Changes and Policies That Encourage Medical Innovation
Date:3/9/2011

TOKYO, March 9, 2011 /PRNewswire/ -- To address growing unmet medical needs and strengthen the global economy, new approaches to biopharmaceutical research and policies that support innovation are critical, according to John Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company (NYSE: LLY).

In remarks to the U.S./Japan Business Council Wednesday in Tokyo, Lechleiter outlined two imperatives to secure the future of the research-based pharmaceutical industry and help stimulate the global economy: changing the way companies conduct research – or "reinventing invention" – and implementing public policies that promote an environment in which medical innovation can thrive.  

Lechleiter said that innovation is a key element in "re-energizing our economies and meeting the growing needs of aging populations."  He added that the aging of society has progressed farther in Japan than anywhere else in the world and that poses a particular challenge:

  • As of September 2010, Japan counted nearly 45,000 people over the age of 100.
  • According to a UN survey, by 2050 Japan is expected to have 272,000 centenarians, although some predict the number could be closer to 1 million, and 40 percent of the Japanese population will be 65 or older.  
  • As Japan ages, demand for medical care will triple in the next 25 years, according to the international consulting firm McKinsey & Co.

Lechleiter noted that a report issued last year on Alzheimer's disease said that the global costs for caring for people with dementia in 2010 would surpass $600 billion – equal to about 1 percent of the world's GDP.  Other research has found that the direct costs of dementia care in Japan are higher than in any other country except the United States.

With these global challenges in mind, Lechleiter made a case for the value of biopharmaceutical research a
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lilly Marks Major Milestone for Mirror Portfolio with Agreement by Independent Fund to License First Two Investigational Medicines
2. Lilly Announces Senior Leadership Changes
3. Lilly CEO Says Industry, Public Policy Must Pave Way For Innovation
4. Lilly and the Juvenile Diabetes Research Foundation Partner to Fund Regenerative Medicine Research in Type 1 Diabetes
5. Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
6. Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance
7. Statement from Lilly and Avid on FDA Advisory Committee Recommendation for Amyvid™ (Florbetapir) NDA
8. Cognizant Selected by Lilly to Deliver Commercial Operations Solutions to Enhance Sales and Marketing Effectiveness, Business Performance
9. Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2010 Financial Results Announcement
10. Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application for Treatment of Exocrine Pancreatic Insufficiency
11. Lilly Announces Completion of Avid Acquisition and FDA Priority Review for florbetapir
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)...  Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is ... the securities of AMAG Pharmaceuticals Inc. ("AMAG" or ... advised to contact Peretz Bronstein or ... at info@bgandg.com or 212-697-6484. ... its officers and/or directors have violated Sections 10(b) ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4rvprn/ddimer_testing ) ... Testing Market - Global Industry Analysis, Size, Share, ... report to their offering. ... one of the fastest growing markets globally. This ... health care awareness, preference of the people for ...
(Date:7/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/65t478/gprotein_coupled ... "G-Protein Coupled Receptors Market: Global Industry Analysis, Size, ... report to their offering. ... on of assay type, therapeutic area, and geography. ... been categorized into six major segments: cAMP assays, ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals Inc. 2D-dimer Testing Market - Global Industry Analysis 2015 2D-dimer Testing Market - Global Industry Analysis 2015 3G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 2
... Transplant Patients Represents First, Pivotal Study on a New Antiviral CMV Therapy in Stem Cell ... Over a Decade ... ... 29 ViroPharma Incorporated,(Nasdaq: VPHM ) today announced that it completed enrollment in its pivotal,Phase ...
... be Presented at ASCO Shows Survival Benefit in Complete ... Partial Responders Compared with Chemotherapy Alone, BERKELEY ... GNTA) announced the results of long-term,followup from a Phase ... sodium) Injection, in patients with chronic,lymphocytic leukemia (CLL). With ...
Cached Medicine Technology:ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 2ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 3ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 4ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 5ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 6Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 2Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 3Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 4
(Date:7/27/2015)... , ... July 27, 2015 , ... ... Step One, **FDAnews Webinar**, Aug. 13, 2015 — 1:30 p.m. – 3:00 p.m. ... of the first things FDA investigators will look at during an inspection. ...
(Date:7/27/2015)... ... July 27, 2015 , ... On July 14, 2015, Harper’s Bazaar ... Issues,” describes common skin issues such as stretch marks , fine lines ... treat them. The treatment options listed include lasers, ultrasound, radio frequency, Botox, and dermal ...
(Date:7/27/2015)... ... July 27, 2015 , ... North Central Surgical Center Hospital will be holding ... all those prospective joint-replacement patients, along with their friends and family members, to attend. ... classes (Aug 6, Sept 8 [Tue due to Labor Day], Oct 5, Nov 2, ...
(Date:7/27/2015)... , ... July 27, 2015 , ... David Gilmour ... He will be performing for one additional night at each of his original four ... DAVID-GILMOUR-2016 for added savings. , David Gilmour’s 2016 North America tour dates: , Thursday, ...
(Date:7/27/2015)... ... July 27, 2015 , ... In an ongoing ... to its options. Already an industry leader because of its use of ... for the latest successful trends in helping people to overcome addiction and live ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 2Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 3Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 4Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:North Central Surgical Center Hospital to Hold Joint Wellness Classes 2Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 3
... The schools in the US appear to be suffering from ... single nurse only. There are about 56,000 nurses working across ... to one nurse for every 950 students, while the federal ... nurse to student ratio is the worst in Utah, when ...
... acquitted on Wednesday of murdering three of his patients with ... a retired army officer from North Wales, was found not ... of three seriously ill men, after a six-week trial. No ... the deaths of other patients under the care of Dr ...
... The vice president of Sandia National Laboratories, Gerry Yonas was the ... ,This led to the development of the BiNational Sustainability ... at Santa Teresa. This will mainly augment the border security ... Canada & Mexico. ,The monetary inputs for ...
... community medicine and colleagues developed the latest tool for identifying ... tool which is called the Newest vital sign. It is ... an ice cream nutrition label. Based on the number of ... be calculated. , Then it is for the ...
... gobbi and his team from Universite de Montreal ... the level of endocannabinoids by blocking the degradation ... chemicals present in brain which is responsible for ... receptors are triggered during exercises and other well-being ...
... the Annals of Internal Medicine this week have found ... the verge of kidney failure is useless. //The study ... in London, Canada found that a treatment called "plasma ... ,This means that the money which is ...
Cached Medicine News:Health News:School Children Put To Risk Due To Shortage Of Nurses 2Health News:British Doctor cleared of murder 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: